SCHEMBL6093905

SCHEMBL6093905

Cc1cc(C)c(-c2cccn3c2cc2nc(C)nc(NCCN)c23)c(C)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY1R P25929 1/20 0.35
IKBKB O14920 6/20 0.35
CHUK O15111 5/20 0.35
CDK11B P21127 2/20 0.35
CDK7 P50613 2/20 0.35
CDK13 Q14004 2/20 0.35
MAP3K19 Q56UN5 2/20 0.35
MYLK4 Q86YV6 2/20 0.35
CDK11A Q9UQ88 2/20 0.35
ERN1 O75460 1/20 0.35
RPS6KA4 O75676 1/20 0.35
PRKD3 O94806 1/20 0.35
CDK1 P06493 1/20 0.35
KIT P10721 1/20 0.35
CDK2 P24941 1/20 0.35
TYK2 P29597 1/20 0.35
CSNK1D P48730 1/20 0.35
CDK9 P50750 1/20 0.35
LIMK1 P53667 1/20 0.35
CDK16 Q00536 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095564 0.84 NPY1R (0.42) NPY1RALDH1A1
SCHEMBL6093439 0.83 NPY1R (0.40) NPY1RIKBKBCHUKCDK11BCDK7
SCHEMBL6092967 0.78 PTPN1 (0.35) ALDH1A1
SCHEMBL6093564 0.78 CDK5 (0.32)
SCHEMBL6092887 0.71 PTPN1 (0.37) CRHR1ALDH1A1
SCHEMBL6095943 0.71 LMNA (0.36) CRHR1ALDH1A1
SCHEMBL7009301 0.65 MAPT (0.40) ALDH1A1
SCHEMBL6094470 0.63 CRHR1 (0.33) CRHR1ALDH1A1
SCHEMBL6094492 0.62 CRHR1 (0.56) NPY1RCRHR1
SCHEMBL7788894 0.62 CRHR1 (0.62) NPY1RIKBKBCHUKCDK11BCDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074929-B2 Certain alkylene diamine-substituted heterocycles NEUROGEN CORP. (US) 2006-07-11 US disclosed
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2004-11-18 US disclosed
US-6696445-B2 NEUROPEPTIDE Y RECEPTOR ANTAGONISTS COMPRISING HETEROCYCLIC NITROGEN COMPOUNDS AND/OR PRODRUGS USED FOR PROPHYLAXIS OF EATING AND CARDIOVASCULAR DISORDERS NEUROGEN CORPORATION 2004-02-24 US disclosed
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2003-08-21 US disclosed
US-6506762-B1 Mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. Novel compounds are for eating NEUROGEN CORPORATION 2003-01-14 US disclosed
EP-1224187-A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES NEUROGEN CORPORATION (US) 2002-07-24 EP disclosed
WO-2001023389-A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES NEUROGEN CORPORATION (US) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R NPY1R 1/4885IKBKB 2393/4885CHUK 586/4885
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R NPY1R 1/4885IKBKB 2336/4885CHUK 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.